Press release -
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
Suzhou Ribo Life Science and Ribocure AB are excited to share that we have achieved a key pre-clinical milestone in our siRNA programs, less than a year into our collaboration with Boehringer Ingelheim.
These achievements highlight the strength of Boehringer Ingelheim’s expertise in MASH and validate the power of the Ribo platform and organization. We are looking forward to advancing these and our collaboration programs into 2025 and beyond to address high unmet patient needs.
